Sio Gene Therapies Inc. buy tamam
Start price
31.08.17
/
50%
€143.67
Target price
09.01.18
€144.32
Performance (%)
-88.37%
End price
09.01.18
€16.71
Summary
This prediction ended on 09.01.18 with a price of €16.71. Massive losses of -88.37% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Sio Gene Therapies Inc. | - | - | - | - |
iShares Core DAX® | 1.851% | 5.158% | 17.711% | 19.954% |
iShares Nasdaq 100 | 1.573% | 2.589% | 39.053% | 56.636% |
iShares Nikkei 225® | -0.412% | -2.857% | 13.501% | 7.721% |
iShares S&P 500 | 1.128% | 2.485% | 29.871% | 47.507% |
Comments by tamam for this prediction
In the thread Sio Gene Therapies Inc. diskutieren
tamam stimmt der Outperform-Einschätzung der institutionellen Analysten zu
One of the most watched trial results on the horizon is for Intepirdine targeting Alzheimers'. Phase 3 data is out from Axovant Sciences by the end of September. Positive results would trigger a massive rally in the stock. I am not sanguine simply because this disease area has the highest failure rate in the industry.
(Vom Mitglied beendet)